announcements

⚡ Flash Summary

Citi Pharma Limited’s financial results for the quarter ended September 30, 2025, reveal a mixed performance. Revenue increased slightly compared to the same period last year, but profitability metrics show a decline. The company reported a decrease in profit before income tax, and the earnings per share saw a marginal increase. While the balance sheet remains relatively stable, cash flow from operating activities has significantly decreased, raising concerns about short-term liquidity.

📌 Key Takeaways

• ✅ Revenue increased to PKR 3,370.25 million in Q3 2025 from PKR 3,224.64 million in Q3 2024, a 4.52% increase.
• 📉 Gross profit increased to PKR 518.97 million in Q3 2025 from PKR 428.51 million in Q3 2024, a 21.11% increase.
• 📉 Operating profit rose to PKR 420.36 million in Q3 2025 from PKR 341.42 million in Q3 2024, a 23.12% increase.
• ⚠️ Financial charges increased significantly to PKR 121.19 million in Q3 2025 from PKR 64.57 million in Q3 2024, a 87.67% increase.
• 📉 Profit before income tax decreased to PKR 302.28 million in Q3 2025 from PKR 340.29 million in Q3 2024, a 11.17% decrease.
• ⚠️ Profit after income tax increased to PKR 203.69 million in Q3 2025 from PKR 201.50 million in Q3 2024, a 1.09% increase.
• 📈 Earnings per share (EPS) increased slightly to PKR 0.89 in Q3 2025 from PKR 0.88 in Q3 2024.
• ⚠️ Cash and bank balances decreased to PKR 23.15 million as of September 30, 2025, from PKR 603.55 million as of June 30, 2025.
• 📉 Short term investments decreased to PKR 892.35 million from PKR 956.39 million.
• 📉 Total Equity increased to PKR 11,071.27 million as of September 30, 2025, from PKR 10,867.58 million as of June 30, 2025.
• 📉 Cash flow from operating activities significantly decreased to PKR -463.73 million in Q3 2025 from PKR -54.42 million in Q3 2024.
• ⚠️ Cash and cash equivalents decreased to PKR 910.95 million as of September 30, 2025, from PKR 1,201.76 million as of September 30, 2024, and PKR 1,491.47 million as of the beginning of the period.
• No cash dividend, bonus shares, or right shares were declared for the quarter.
• Total assets decreased to PKR 17,866.96 million as of September 30, 2025, from PKR 18,439.45 million as of June 30, 2025.

🎯 Investment Thesis

HOLD. The mixed financial performance and concerning decrease in cash flow from operating activities warrant a cautious approach. While revenue has increased, the profitability metrics and liquidity issues raise concerns. A HOLD recommendation is appropriate until the company demonstrates improved cost management, enhanced operational efficiency, and stronger cash flow generation. Further monitoring of financial charges and working capital management is essential.